Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 119HER2-positive Breast Cancer 10Stomach Neoplasms 9Neoplasm Metastasis 6Neoplasms 4Inflammatory Breast Neoplasms 4Esophageal Neoplasms 3Adenocarcinoma Of Esophagus 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Invasive Breast Cancer 2HER2-positive Metastatic Breast Cancer 2HER2-positive Early Breast Cancer 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Solid Tumors 1Resectable HER2-positive Breast Cancer 1Patient Preference 1Pathologic Complete Response 1Osteitis Deformans 1Metastatic HER2-positive Breast Cancer 1HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1HER2-positive Gastric Cancer 1HER2-positive Carcinoma of Breast 1HER2-positive Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Early or Locally Advanced Breast Cancer 1HER2 Positive Early Breast Cancer 1Endometrial Neoplasms 1Early-stage or Locally Advanced HER2-positive Breast Cancer 1Early or Locally Advanced HER2-positive Breast Cancer 1

Interventions

Fluorouracil 72Leucovorin 71Oxaliplatin 47Irinotecan 31Capecitabine 24Bevacizumab 23Folfox protocol 20Cetuximab 15Chemotherapy, Adjuvant 13Celecoxib 7Aspirin 6Laparoscopy 5XELOX 4Panitumumab 4Neoadjuvant Therapy 4Levamisole 4dehydroftorafur 3Tegafur 3Surgical Procedures, Operative 3Observation 3Floxuridine 3vatalanib 2tislelizumab 2pertuzumab 2encorafenib 2atezolizumab 2Trastuzumab 2Standard of Care 2Semaxinib 2Selenium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Colonic Neoplasms × Trastuzumab × Clear all
NCT03803553 2026-05-01

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Massachusetts General Hospital

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06490536 2025-08-29

The Sagittarius Trial

IFOM ETS - The AIRC Institute of Molecular Oncology

Phase 3 Recruiting
700 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡